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MDAnderson
Stereotadic Unit Expands Treatment
Options for Patients with Brain Tumors
by Dawn Chalaire

romisingresults .
achieved using
stereotactic radiosurgery (SRS)
and increased demand for
the procedure have l,ed to the
opening of a new Stereotactic
Unit at The University of
Texas M. D. Anderson Cancer
Center and to the development
of stereotactic techniques that
can be used to treat brain
tumors that are not amenabl,e
to conventional SRS.

P

Associate Professor of Radiation Physics Almon Shiu, Ph.D., (right) and Moshe Maor,
M.D., a professor in the Department of Radiation Oncology, examine the miniature
multileaf collimator (MMLC) component of the Stereo tactic Unit's new linear accelerator:
The MMLC, designed by Dr: Shiu, is used to deliver conformal stereotactic procedures.

In contrast to standard radiation therapy, which is given in
small, daily doses over a period
of weeks, SRS delivers a high dose
of radiation to a small volume of
tumor in a single treatment.
"A higher degree of accuracy is
required with stereotactic radiosurgery than with standard radiation
therapy because the target is
smaller and because you have only
one opportunity to get it right,"
(Continued on page 2)

Stereotadic Unit Expands Options
( Continued from page 1)

gery- particularly Raymond Sawaya,
said Moshe Maor, M.D., a professor
M.D ., Samuel Hassenbusch, M.D.,
in the Department of Radiation
Ph.D., and Frederick Lang, M.D.Oncology and director of the new
is essential when performing SRS.
Stereotactic Unit.
Plans are in place to open a dediThe high, concentrated dose of
cated SRS clinic, which will be
radiation delivered in SRS is made
located within the Neuro Center.
possible by the precise convergence
In the new clinic, patients will be
of beams of radiation to one focal
seen simultaneously by Dr. Maor and
point, the patient's tumor. The
Dr. Hassenbusch, the neurosurgeon
radiation beams are delivered by
in charge of SRS, to streamline the
a linear accelerator from different
selection of candidates for the
The MMLC contains
points along multiple arcs of rotaprocedure.
tion. The treatment couch also
a series of very thin
Almon Shiu, Ph.D. , an associate
rotates 180 degrees, making possible
professor in the Department of
many angles of rotation. The precitungsten leaves that
Radiation Physics, has been overseesion of SRS produces a sharp dose
ing the technical development of SRS
gradient between the target and
can be programmed
at M. D. Anderson from the beginsurrounding area, allowing a much
using a threehigher dose of radiation to the
ning. Dr. Shiu helped develop the
tumor with minimal damage to
current table-mounted system and
dimensional planning
surrounding normal brain tissue.
table-supporting device, and in 1991
"The full radiation dose falls to
he began designing the miniature
system to conform
negligible levels within a few millimultileaf collimator (MMLC) system.
to the contours
meters outside the target. Such
The MMLC contains a series of
precision cannot be achieved with
very thin tungsten leaves that can be
of irregularly
any other method. Being able to
programmed using a three-dimendeliver a high, concentrated dose
shaped tumors.
(Continued on page 4)
to the tumor enables us to overcome
the tendency of some tumors to
resist radiation," Dr. Maor said.
- - - - - PROTOCOLS-- - At M. D. Anderson, SRS is most
commonly used to treat patients with
1 or 2 primary or metastatic brain
recurrent pri mary brain tumors or new
tumors that are smaller than 4 cm in
or recurrent brain metastases. Patients
diameter and not surgically accessible.
must be older than 16 years and have a
Studies of SRS show tumor regression
Zubrod performance status of 2 or more
in 70% of patients, Dr. Maor said, and
and a life expectancy of at least three
in two-thirds of patients with brain
months. Patients with primary or
metastases, neurological deterioration
metastatic
tumors outside the brain
can be avoided.
Clinical trials in progress at The Univermust
have
stable disease. Magnetic
M. D. Anderson has been perform.
ing SRS since 1991, but steadily
~1ty of Texas M. D_. Ande_rson Cancer ~enter
resonance imaging of the brain per·ncreasing-demand-forthe---prucedure- _ mclude tbeJ ollowmg usmg_stereotactIc __
-~formed wiH1in -H1ree-weeks-of-treatment -over the past few years has led to the
treatment techniques, surgical procedures,
planning must show a well-defined
purchase of a new linear accelerator
and radiation therapy for patients with
tumo r. Patients may not undergo
that will be used exclusively for SRS
brain tumors.
che motherapy for three weeks prior
procedures. With the dedicated linear
to treatment until one month after
accelerator, more than one SRS
• Phase I study of stereotactic fractionated
the last fraction.
treatment can be performed each day.
radiotherapy using a miniature multileaf
The dedicated machine has the same
collimator (MMLC) and a relocatable
• A randomized, phase Il l trial of surgery
capabilities as the department's other
frame for the treatment of brain tumors
vs. stereotactic radiosu rgery in the
linear accelerators, along with a more
(ID97-011). Physician: Moshe H. Maor,
treatment
of single brain metastases
stable treatment couch and the ability
M.D.
(NS97-1
99).
Physician: Frederick Lang,
to deliver intensity-modulated radiaParticipants
will
receive
rad
iotherapy
M.D.
tion therapy.
treatments on an outpatient basis for
Dr. Maor said that collaboration
with the Department ofNeurosur-

Brain Tumor Protocols
Include Stereotadic
Treatments, Surgery,
and Radiation Therapy

2 / MD Anderson OncoLog

Accuracy
sential in
Stereotadic
adiosurgery
im Lii holds a
magnifying glass
in front of one eye
and stares intently at the
image of a laser beam that
appears to be exactly in
th e center of a pair of
tiny lines engraved on a
target that is mounted
on top of a mechanical
isocenter stand in a
radiation therapy treatment room. He is not
satisfied.
''You see how the laser
beam is touching the
line?" Lii asks. "It should
n ot be touching."
As Lii makes miniscule
adjustments to the wall-

mounted laser by remote
control, fe llow medical
physicist Jin-Song Ye
explains that the beam is
between 0.10 and 0.20
mm from the isocenter,
well within the allowable
accuracy of 0.25 mm.
"But Jim is trying
to be exact," Ye says.
The two medical
physicists are performing
a quality assurance check
in preparation for a
stereotactic radiosurgery
procedure at The U niversity of Texas M. D. Anderson Cancer Center. They
have spent the morning
participating in the
acquisition of a patient's
computed tomographic
images, performing
treatment planning on a
computer, and transfer-

ring the BRW coordinates
of the center of the
treatment target to a
metal frame known as
a rectilinear phantom
pointer (RLPP), which
serves as a model of the
patient's head. The RLPP
is attached to a laser
target localizer frame and
to the treatment couch of
the linear accelerator. A
tungsten ball is placed
within the RLPP in the
exact location of the
center of the treatment
target within the patient's
head, and film shots are
taken to verify its alignment. During SRS, all
the radiation beams will
crossfire through the
center of this point.
Lii and Ye spend
30-45 minu tes applying

the same sub-millimeter
precision to checking
and double-checking the
positions of the RLPP,
the laser target localizer
frame, and the treatment couch durin g the
patient's treatment. T hey
even make adjustments
to allow for the weight
of the machine's gantry
as it rotates arou nd th e
treatment couch , the
weight of the patient's
h ead, and th e ever-soslight tilt of the treatment
couch.
"Everything we do
here is for one purpose,"
Ye says. 'We want to place
the center of the treatment
target, the patient's tumor,
at the radiation isocenter
of the linear accelerator." •

- - - - PROTOCOLS---Patients aged 16-75 years with newly
diagnosed single brain metastases who
are candidates for both conventional
surgical resection and stereotactic
radiosurgery (SRS) will be randomly
chosen to undergo surgery or SRS.
After the initial procedure, patients will
return for follow-up once a month for
the first two months and then every two
months thereafter. Patients must have a
life expectancy of at least four months,
be able to care for themselves, have
adequate bone marrow and platelet
function, and have no active, uncontrolled infection. Patients who require
immediate treatment to prevent neurological deterioration are not eligible for
this study. Evidence of leptomeningeal
disease, prior radiation therapy to the
brain, prior radioiodine treatment, and a
primary tumor that is extremely radiosensitive are all criteria for exclusion.

Patients who are pregnant or breastfeeding are ineligible.
• A prospective randomized trial of
surgery with whole-brain radiation
therapy versus whole-brain radiation
therapy alone in the treatment of
multiple brain metastases (!098-028) .
Physician: Raymond Sawaya, M.D.
This phase 111 study includes both
inpatient and outpatient procedures for
patients with newly diagnosed multiple
brain metastases determined by MRI.
Patients will return for follow-up at one
month and two months after treatment
and every two months thereafter. To
participate, patients may have no more
than three lesions, and all lesions must
be resectable. A life expectancy of at
least four months is required , and
patients must be candidates for conventional surgical resection . If a neurosur-

. geon and radiation onco.logist determine
that all of a patient's brain tumors
necessitate surgical resection , the
patient is not eligible. Patients who have
an extremely radiosensitive primary
tumor, have received prior radiation
therapy to the brain or prior radioiodine ,
have evidence of leptomeningeal
disease, or are pregnant or breastfeeding are ineligible. •
about these clinical
trials, physicians or patients may call
the M. D. Anderson Information Line.
Those within the United States should
call (800) 392-1 611; those in Houston
or outside the United States should
call (713) 792-6161 . Visit the M. D.
Anderson Cancer Center clinical trials
web site at http://www.clinicaltrials.org
for a broader listing of treatment research
protocols.
FoR MORE INFORMATION
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Stereotadic Unit
Expands Options
(Continued from page 2)

sional planning system to conform
to the contours of irregularly shaped
tumors, blocking radiation to normal
tissue. Conformal SRS, using the
MMLC attached to the gantry of the
dedicated linear accelerator, delivers a
high dose of radiation in one fraction
with a single isocenter. In conventional SRS, a circular collimator
focuses the beam of radiation on the
tumor. If the tumor is large or irregularly shaped, two or more isocenters
must be used for the treatment.
"Using the circular collimator in
such instances is not advantageous
because when using more than one
isocenter, the overlapping radiation
fields result in a high dose," Dr. Shiu
said. "The overlapping area receives
twice the peripheral dose, which
could lead to complications."
The MMLC can also be used with
stereotactic fractionated radiation,
which uses the same multiple-arc
technique as SRS to deliver small doses
of highly conformal radiation in
multiple fractions. Stereotactic fractionated radiation is used for tumors
larger than 4 cm or when maximum
sparing of normal tissue is critical.
The standard SRS head frame,
which a neurosurgeon attaches to
the patient's skull by four pins,
cannot be used with stereotactic
fractionated radiation because
treatment is extended over a few
weeks. Instead, a frame that attaches
through a bite block that can be held
in the patient's mouth was developed. Although the bite block does
not ensure the same exactness as the
surgical head frame, it achieves more
than satisfactory reproducibility,
Dr. Maor said.
Researchers at M. D. Anderson
are also developing a body frame that
will be used to immobilize patients
during SRS for metastatic spine,
lung, and liver tumors. According
to Dr. Maor, SRS is effective against
these metastases if they are small
and isolated. •
contact Dr: Maor
at (713) 792-3410 or Dr: Shiu at (713)
792-3292.

FoR MORE INFORMATION,

4 / MD Anderson OncoLog

New Center Teams with Co1
to Treat Patients with Adva
by Dawn Chalaire

atients with
advanced_ cancer
can experience
many severe
symptoms-pain, fatigue,
chronic nausea, lack of
appetite, and malnutritionsimultaneously. In addition,
these patients and their families
must cope with emotional
distress and face what may
seem like a never-ending
parade of difficult decisions.

P

"The patient needs a combination
of very well planned control of
physical symptoms and emotional
support, and the family needs to see
that the patient is well treated, from
both the physical and emotional
points of view," said Eduardo Bruera,
M.D., director of the newly established
Symptom Control and Palliative Care
Center at The University of Texas
M. D. Anderson Cancer Center. "The
family needs support and validation
of their own fears and concerns.
They also need to address some of
the issues regarding the duration of
the patient's life and anticipate and
plan for the care that the patient
will need."
Working in partnership with
community physicians, the Symptom
Control and Palliative Care Center
provides multidisciplinary assessment
. and management strategies to control
and alleviate the severe symptoms
faced by patients with advanced
cancer and offers support and
counseling for family members.
"The goals of the center are
to treat patients who have very
advanced and incurable cancer,"
said Dr. Bruera, "and to help and
empower all other centers and all
other oncologists and practitioners
in our area of influence to feel more

comfortable with the assessment
and treatment of these patients."
Most p atients will be referred to
the center, which officially opened
the second week in October, by
physicians at M. D. Anderson, Dr.
Bruera said, although a small number may be referred by other physicians in the Houston area. Because
most of the patients seen at the
center are extremely weak and
frequently have symptom distress,
the center has private rooms with
bathrooms and full-size beds. The
center does not, however, have a
waiting room; as soon as patients
and family members arrive, they are
taken to a private room where they
are provided e ducational videos and
computer programs to view between
consultations. During their half-day
stay at the center, patients are visited
by a physician, nurse, pharmacist,
physical therapist, occupational
therapist, nutritionist, psychologist,
pastoral care representative, and
social worker.
"The representatives of each
discipline offer their support, make
an assessment, and meet together to
discuss the strategy to be proposed to
the patient and family. Then, a series
of recommendations and suggestions
are given to the patient and family
and sent to the patient's primary care
physician and community nurse,"
Dr. Bruera said.
All patients are provided with
written, as well as verbal, recommendations and an audiocassette that
summarizes the main recommendations so that the patients can share
the information with their families.
Some patients will require follow-up
at the center, while other patients
will be referred back to their primary
care physicians. Patients who return
to the center receive a two-hour
assessment by a physician, nurse, and
pharmacist. Two-hour assessments
are also available for patients who
do not require a half-day stay at the
center. Patients visiting the center for

mmunity Physidans
1nced Cancer
"The patient needs a
combination of very well
planned control of
physical symptoms and
emotional support, and the
family needs to see that the
patient is well treated:'
- Eduardo Bruera, M.D., director, Symptom
Control and Palliative Care Center
Before a treatment rearmmendation is made,
patients with a,dvanced r,anc.er are eualuat,ed
by representativesfrom several disci,p!ines in
the Symptom Control and Palliative Care
Center. Eduardo Bruera, M.D., renter director;
also amducts an initial interview efeach
patient wlw is referred to the outpatient renter.
either half-day or two-hour assess
ments may receive treatments or
undergo tests before being referred
back to their primary care physicians.
A 13-bed, tertiary palliative care
unit designed to stabilize patients
with severe symptom distress is
scheduled to open in the spring of
2000 on the same floor as the outpa
tient center, Dr. Bruera said. Once
their symptoms are under control,
patients will leave the unit and return
to their local hospital or hospice or,
occasionally, home.
'That will make for a very nicely
integrated setting," Dr. Bruera said.
"On the same floor, we will have the
nursing staff, support staff, and facili
ties, as well as a common theme and
integrated policies and procedures."
In addition to offering specific
treatment strategies for individual
patients, the Symptom Control and
Palliative Care Center educates
community physicians about caring
for patients with advanced cancer
through lectures, courses, and
symposiums. A major palliative care
conference is scheduled for June 2

and 3, 2000, and beginning in
April 2000, the center plans to offer
four-hour Internet courses for
Continuing Medical Education
credit. Information about the
center's educational offerings can
be found on its home page at
www.mdanderson.palliative.org.
"Contrary to other centers that
mainly provide treatment, we see
ourselves as having less of a direct
treatment role and a major educa
tional role," Dr. Bruera said.
Dr. Bruera and others in the
center are also working to expand
on the limited research available on
the causes and treatments of many of
the devastating symptoms associated
with advanced cancer. Dr. Bruera,
who came to M. D. Anderson in July
1999 after spending 15 years as a
professor of oncology at the Univer
sity of Alberta in Edmonton, Alberta,
Canada, will continue his research in
several areas related to palliative care.
"The questions that we are
addressing in our research cover a
broad spectrum," Dr. Bruera said.
"They include: How can we prevent

cachexia and fatigue? What is the
best communication strategy? Which
medications are the most effective?
What models of health service
delivery make access to care most
effective? All of these questions are
focused on treating patients with
advanced cancer."
Incorporated into the new
Symptom Control and Palliative
Care Center are the Pain Research
Group and the Physical Medicine
and Rehabilitation Group. The Pain
Research Group has contributed a
body of work to the new center that
includes studies of the best ways
to assess pain and other symptoms.
The Physical Medicine and Rehabili
tation Group helps all patients with
cancer, including those whose cancers
are incurable, express their maxi
mum physical and psychosocial
function and assists patients who
have undergone successful aggressive
cancer treatments in returning to
a productive and effective life. •
FOR MORE INFORMATION,

at (713) 792-6085.

contact Dr. Bruera
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IRS Dedudion Gives Smokers
One More Reason to Quit
by Alison Ruffin and Vickie Williams

igarette smokers and
users of smokeless
tobacco now have yet
another incentive to
break the habit. Under new
Internal Revenue Service
guidelines, the cost of tobacco
cessation programs and associated prescription medications
can be claimed as income tax
deductions. These items are
now considered ''Deductible
Medical Expenses" and can be
itemized under this category on
the yearly income tax statement.

C

Allowable deductions include
expenses for prescription medications such as antidepressants, which
are often included in tobacco cessation regimens; tobacco cessation
programs; and physician's fees.
However, non-prescription smoking
cessation aids such as nicotine
patches and gum are not deductible.
"We hope this endorsement at
the federal level will spur insurance
companies and managed care
companies to offer coverage for
tobacco cessation programs," commented Bernard Levin, M.D., vice
president for cancer prevention
at The University of Texas M. D.
Anderson Cancer Center.
Dr. Paul Cinciripini, Ph.D.,
director of tobacco research and
treatment at M. D. Anderson, said
that the tax deductions are a small
step in the right direction.
"This will help some people
receive reimbursement for important
prevention services," Dr. Cinciripini
said, "but far more should be done
to address the need for insurance
coverage of tobacco cessation programs."
An example of an allowable
deduction is the service provided
6 / MD Anderson OncoLog

"We're very glad to see
such a broad-brush incenYou may include in
.
tive," said Therese Bevers,
unreimbursed costs~ed,cal e~penses
M.D.,
medical director of
sation programs
or smoking cesM.
D.
Anderson
's Cancer
drugs designed tin1, to~ pres_cription
Prevention Center, h ome
withdrawal.
a ev,ate nicotine
to the Tobacco Cessation
Clinic. "This may be just the
right form of encouragement
to help many tobacco users kick
through M. D. Anderson's Tobacco
the habit." •
Cessation Clinic. At the clinic,
patients receive individualized
FOR MORE INFORMATION about M. D.
counseling in a six- to eight-week
Anderson
's Tobacco Cessation Clinic,
program that costs about what
call
(713)
745-8040 or (800) 438most pack-a-day smokers spend
6434.
on cigarettes in six months.

Smoking Cessation

lmpad of Tobacco Use
• Tobacco use is responsible for 35%
of all cancer-related deaths and is
the chief avoidable cause of illness
and death in the United States.
• Tobacco use causes more deaths annually
than alcohol, heroin, cocaine, suicide,
homicide, automobile accidents, fires,
and Al DS combined.
• In 1999, an estimated 158,900 Americans will die of lung cancer,
and an estimated 171,600 Americans will be diagnosed with the disease.
• Lung cancer kills more women each year than breast cancer. In the
United States, an estimated 68,000 women will die of lung cancer in 1999,
whereas 43,300 will die of breast cancer.
• Every day, more than 3,000 children and adolescents become addicted
to tobacco.
• About 25% of Americans (48 million people) currently smoke, and about
one-fifth of high school seniors in the United States smoke.
• The estimated annual cost for smoking-related medical care is $50 billion,
with the cost of lost productivity and forfeited earnings due to smokingrelated disability estimated at another $50 billion per year.
• Roughly one-third of M. D. Anderson patients receive treatment for
tobacco-related cancers.
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Vitamins and cancer Risk: Why You
~t:_~ S~ho~u~ld~E~at~~~ou~r~(F~ru=its
=-=an_d..):. _~-e~get
_a_b_le7s

ur mother was rioht:
o·
Fruits and vegetables
are good for you.
O

and C for possible protection against
cancers of the throat, stomac h , a nd
lungs and some skin cancers. ~oods
high in vitamin A include apricots,
cantaloupe, carrots, romaine lettu~e,
mangoes, mustard greens, pumpkm,
spinach, sweet potatoes, and winter
squash.

In fact, there is over_whelming evidence that eating
fruits and vegetables can help
dec:ease you_r risk of devel~
oping certain cancer~.
While it is clear that die ts ;r:__ ~

r& ~0,

(arotenoids. ~esearc_hers

have also been mvest~gating the cancer-reducmg
that include a wide variety of
[ ' \ ~ / \ effects of carotenoids,
fruits and vegetables protect ~ . . . ,
chemicals that are
against several types of
~
synthesized by plants.
cancers, determining which
Diets high in carotenoids
constituents of fruits and vegprobably decrease the risk of
etables are responsible for the
lung cancer and also may decrease
decreased risk is more difficult.
the risk of esophageal, stomach,
colorectal, breast, and cervical
Vitamin C. There is convincing
cancers, according to the American
evidence that vitamin C decreases
Institute for Cancer Research's Food,
the risk of developing cancers of
Nutrition, and the Prevention of Cancer:
the larynx, esophagus, stomach, and
A Global Perspective.
pancreas, according to an analysis
Beta-carotene is a carotenoid that
of studies of vitamin C published in
is found mainly in yellow-orange
Nutrition and Cancer Prevention. In
vegetables and fruits and in dark
addition, the authors concluded that
green, leafy vegetables.
dietary vitamin C possibly decreased
Other carotenoids are
the risk of lung cancer in nonfound in tomatoes,
smokers and the risk of
watermelon, pink
cancers of the oral cavity,
grapefruit, pumpkin,
rectum, and cervix.
grapes, eggplant,
Eating foods high in
and some berries.
vitamin C seems to have a
more beneficial effect than Vitamin E. An American Institute
taking vitamin C supplefor Cancer Research panel also
ments, probably because there
found that diets high in vitamin E
are additional cancer-protective
possibly decrease the risk of lung and
agents in vitamin C-rich foods. Good
cervical cancers. Vitamin E is found
sources of vitamin C include citrus
in vegetable oils, whole grains, nuts,
fruits, broccoli, cabbage and other
seeds, and wheat germ.
green leafy vegetables, peppers,
tomatoes, potatoes, mangoes,
Antioxidants. Vitamins C and E,
strawberries, and melons.
beta-carotene, other carotenoids,

:Z

Vitamin A. The American
Cancer Society recommends
eating a lot of fru/2its
and vegetables
that are rich in
vitamins A

and the trace mineral selenium have
antioxidant properties. Antioxidants,
scientists theorize, neutralize potentially destructive reactive molecules
called free radicals before they can
attack DNA. By halting free radical
assault, antioxidants may stop

genetic mutations and ~hereby
reduce the risk of certam cancers.

How much is enough?
For cancer prevention, eating a diet
rich in fruits and vegetables is preferable to swallowing vitamin supplements because other components of
fruits and vegetables may also contribute to cancer prevention. Taking
megadoses of a particular vitamin
over an extended period of time
may also be harmful.

The National Cancer
Institute advises
eating five or more
servings of fruits
and vegetables a day.
One medium piece of
fruit or 1/2 cup of fresh
fruit, 3/ 4 cup of 100% fruit
or vegetable juice, 1/ 4 cup of dried
fruit, 1/ 2 cup of raw or cooked
vegetables, and 1 cup of leafy vegetables each count as a single serving.
Surveys show that most people
already eat an average of two to three
daily servings of fruits and vegetables.
Adding an extra two or three servings
a day can be as simple as eating a
banana at breakfast, snacking on
an orange, and having an extra
serving of vegetables with dinner.
The good news is that you can
improve your eating habits at any
age. Whenever you start, you'll begin
to be healthier and reduce your
cancer risk. •

For more information, contact
your physician or contact the
M. D. Anderson Information Line:
({) (800) 392-1611 within
the United States, or
({) (713) 792-6161 outside
the United States.
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Staff Publications
in October
Below is a partial list of staff
publications appearing this
month.
Aguayo A, Cortes], Thomas
D, Pierce S, Keating M,
Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugatedasparaginase, and prednisone in the treatment of
patients with refractory or
recurrent acute lymphoblastic leukemia. Cancer
1999;86(7) :1203-9.
Alemany R, Gomez-Manzano
C, Balague C, Yung WKA,
Curiel DT, Kyritsis AP,
Fueyo J. Gene therapy for
gliomas: molecular targets,
adenoviral vectors, and
oncolytic adenoviruses.
Exp Cell Res 1999;252(1):
1-12.
Ibrahim NK, Rahman Z,
Valero V, Willey J,
Theriault RL, Buzdar AU,
Murray JL 3rd, Bast R,
Hortobagyi GN. Phase II
study of vinorelbine
administered by 96-hour
infusion in patients with
advanced breast carcinoma. Cancer 1999;86(7):
1251-7.
Jacobson K, Rolston K, Elting
L, LeBlanc B, Whimbey E,
Ho DH. Susceptibility
surveillance among gramnegative bacilli at a cancer
center. Chemotherapy
1999;45(5) :325-34.
Jung ID, Nakano K, Liu W,
Gallick GE, Ellis LM.
Extracellular signalregulated kinase activation
is required for up-
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regulation of vascular
endothelial growth factor
by serum starvation in
human colon carcinoma
cells. Cancer Res
1999;59 ( 19) :4804-7.
Krishnamurthy R, Whitman
GJ, Stelling CB, Kushwaha
AC. Mammographic
findings after breast
conservation therapy.
Radiographies 1999;19 Spec
No:S53-62; quiz S262-3.
Lynch PM. Clinical challenges in management of
familial adenomatous
polyposis and hereditary
nonpolyposis colorectal
cancer. Cancer 1999;86
(S8): 1713-19.
Michaud LB, Buzdar AU.
Risks and benefits of
aromatase inhibitors in
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